These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6905865)

  • 41. International Conference on Harmonisation; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Sep; 63(182):50244-9. PubMed ID: 12269373
    [TBL] [Abstract][Full Text] [Related]  

  • 42. I. Federal regulations concerning use of asbestos filters in manufacturing parenteral drugs.
    Casola AR
    Bull Parenter Drug Assoc; 1975; 29(5):216-8. PubMed ID: 1182330
    [No Abstract]   [Full Text] [Related]  

  • 43. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
    [TBL] [Abstract][Full Text] [Related]  

  • 44. View from the Nation's Capital. Investigational new drug (IND) and new drug application (NDA).
    Romansky MA
    J Clin Psychopharmacol; 1983 Jun; 3(3):193-4. PubMed ID: 6680405
    [No Abstract]   [Full Text] [Related]  

  • 45. The authority of a court to order disgorgement for violations of the Current Good Manufacturing Practices requirement of the Federal Food, Drug, and Cosmetic Act.
    King E; Walsh EM
    Food Drug Law J; 2003; 58(2):149-68. PubMed ID: 12866550
    [No Abstract]   [Full Text] [Related]  

  • 46. APHIS biologics personnel hear from constituents, consumers.
    Gloyd JS
    J Am Vet Med Assoc; 1992 Oct; 201(7):976-7. PubMed ID: 1429145
    [No Abstract]   [Full Text] [Related]  

  • 47. Human cells, tissues, and cellular and tissue-based products; donor screening and testing, and related labeling. Interim final rule; opportunity for public comment.
    Food and Drug Administration, HHS
    Fed Regist; 2005 May; 70(100):29949-52. PubMed ID: 15915582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biological products; bacterial vaccines and toxoids; implementation of efficacy review. Final rule and final order.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Jan; 69(2):255-67. PubMed ID: 14968793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Appeals Court says Food and Drug Administration can regulate Cholestin.
    SoRelle R
    Circulation; 2000 Aug; 102(7):E9012-3. PubMed ID: 10960259
    [No Abstract]   [Full Text] [Related]  

  • 50. Takings issues in the approval of generic biologics.
    Yoo JC
    Food Drug Law J; 2005; 60(1):33-43. PubMed ID: 15940853
    [No Abstract]   [Full Text] [Related]  

  • 51. CBER status on reform initiatives: industry reactions and comments.
    Page M
    Food Drug Law J; 1997; 52(2):193-6. PubMed ID: 10557559
    [No Abstract]   [Full Text] [Related]  

  • 52. Making sure biologicals are safe.
    Hecht A
    FDA Consum; 1977; 11(6):21-6. PubMed ID: 10304996
    [No Abstract]   [Full Text] [Related]  

  • 53. The problem with the double-edged solution.
    Czap A
    Altern Med Rev; 2009 Jun; 14(2):96-8. PubMed ID: 19594219
    [No Abstract]   [Full Text] [Related]  

  • 54. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Delegations of authority and organization; Office of the Commissioner--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58758. PubMed ID: 10115698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 57. International Conference on Harmonisation; draft guidance on E2F Development Safety Update Report; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(151):45462-3. PubMed ID: 18949880
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 59. Introduction to the issues: appropriate methods of process validation.
    Scribner CL
    Dev Biol Stand; 1992; 76():213-4. PubMed ID: 1478338
    [No Abstract]   [Full Text] [Related]  

  • 60. Does the FDA have authority to regulate human cloning?
    Price EC
    Harv J Law Technol; 1998; 11(3):619-41. PubMed ID: 12731551
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.